Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 98.3% in November

Apollomics, Inc. (NASDAQ:APLM) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 2,900 shares, a decline of 98.3% from the October 31st total of 168,500 shares. Based on an average trading volume of 283,800 shares, the short-interest ratio is presently 0.0 days.

Hedge Funds Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation boosted its stake in Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the quarter. Apollomics comprises 0.0% of George Kaiser Family Foundation’s portfolio, making the stock its 18th largest position. George Kaiser Family Foundation owned about 0.75% of Apollomics worth $141,000 as of its most recent filing with the SEC. 19.13% of the stock is currently owned by hedge funds and other institutional investors.

Apollomics Stock Performance

APLM remained flat at $8.16 during midday trading on Wednesday. 70,433 shares of the company’s stock were exchanged, compared to its average volume of 92,573. The company’s fifty day moving average price is $13.03 and its 200-day moving average price is $17.48. Apollomics has a one year low of $7.55 and a one year high of $118.00.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.